Write your message
Volume 7, Issue 4 (July - August 2022)                   J Obstet Gynecol Cancer Res 2022, 7(4): 358-360 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Aminimoghaddam S. Response letter to Professor Hemida regarding a published article with the doi of http://dx.doi.org/10.30699/jogcr.4.3.111. J Obstet Gynecol Cancer Res. 2022; 7 (4) :358-360
URL: http://jogcr.com/article-1-633-en.html
Associated Professor, Department of Gynecology, Faculty of Medicine, Iran University of medical sciences, Tehran, Iran , Aminimoghaddam.s@iums.ac.ir
Abstract:   (729 Views)

Response to the editor letter
Dear Professor Behtash,
I am writing this letter to respond to the letter written by Professor Reda Hemida from Mansoura University, Egypt, regarding a publication of mine titled “The Association of Gestational Trophoblastic Neoplasia and Misoprostol Administered Before Suction Curettage of Molar Pregnancy,” published in 2019 in your journal.
I want to first thank Professor Hemida for reading my paper carefully and sharing his comments. I highly believe that sharing comments and raising scientific questions could benefit our society. I hope that the responses that the co-authors have provided be helpful and to the point. As he suggested, I am willing to let the journal publish the responses in the next issue.

Full-Text [PDF 169 kb]   (124 Downloads) |   |   Full-Text (HTML)  (411 Views)  
Systematic Review: Letter to the Editor | Subject: Obstetrics and Gynecology
Received: 2022/01/27 | Accepted: 2022/03/2 | Published: 2022/03/14

1. Hemida R, Misoprostol for Cervical Ripening Prior to Molar Evacuation: A letter to the editor. J Obstet Gynecol Cancer Res. 2022; 7 (4): XX-XX
2. Aminimoghaddam S, Ahmad A, Nassiri S. The Association of Gestational Trophoblastic Neoplasia and Misoprostol Administered Before Suction Curettage of Molar Pregnancy. J Obstet Gynecol Cancer Res. 2019; 4 (3) :111-116. [DOI:10.30699/jogcr.4.3.111]
3. World Health Organization, Safe abortion: technical and policy guidance for health systems. World Health Organization, 2012.
4. Krugh M, Maani CV. Misoprostol. [Updated 2021 Jul 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539873/
5. Saha M, Chakraborty A, Chattopadhyay S, Saha S, Paul J, Das A. Effect of misoprostol for cervical priming before gynecological procedures on nonpregnant premenopausal women. J Nat Sci Biol Med. 2015;6(Suppl 1):S123-S127. [DOI:10.4103/0976-9668.166116]
6. Celik H, Sapmaz E. Use of a single preoperative dose of misoprostol is efficacious for patients who undergo abdominal myomectomy. Fertil Steril. 2003;79(5):1207-1210. [DOI:10.1016/S0015-0282(03)00076-1]
7. Abdel-Hafeez M, Elnaggar A, Ali M, Ismail AM, Yacoub M. Rectal misoprostol for myomectomy: A randomised placebo-controlled study. Aust N Z J Obstet Gynaecol. 2015;55(4):363-368. [DOI:10.1111/ajo.12359]
8. Fiala C, Gemzell-Danielsson K, Tang OS, von Hertzen H. Cervical priming with misoprostol prior to transcervical procedures. Int J Gynaecol Obstet. 2007;99 Suppl 2:S168-S171. [DOI:10.1016/j.ijgo.2007.09.005]
9. Tidy, J, Seckl, M, Hancock, BW, on behalf of the Royal College of Obstetricians and Gynaecologists. Management of Gestational Trophoblastic Disease. BJOG.2021; 128: e1- e27.
10. Flam F, Lundström V, Pettersson F. Medical induction prior to surgical evacuation of hydatidiform mole: is there a greater risk of persistent trophoblastic disease?. Eur J Obstet Gynecol Reprod Biol. 1991;42(1):57-60. [DOI:10.1016/0028-2243(91)90161-D]
11. Paul Duggan et al., "The management of gestational trophoblastic disease," R. Aust. New Zeal. Coll. Obstet. Gynaecol., Mar. 2020.
12. Tidy JA, Gillespie AM, Bright N, Radstone CR, Coleman RE, Hancock BW. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol. 2000;78(3 Pt 1):309-312. [DOI:10.1006/gyno.2000.5839]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2022 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.